Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Abstract Background Non-small cell lung cancer (NSCLC) patients with sensitive epidermal growth factor receptor (EGFR) mutations are successfully treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, resistance to treatment inevitably occurs. Given lipid metabolic reprogramming is widel...

Full description

Bibliographic Details
Main Authors: Quanfu Huang, Qiuguo Wang, Dong Li, Xiao Wei, Yijuan Jia, Zheng Zhang, Bo Ai, Xiaonian Cao, Tao Guo, Yongde Liao
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
NSCLC
EGFR-TKI resistance
Lipid metabolism
Lipid droplet
SCD1
Oleic acid
Online Access:http://link.springer.com/article/10.1186/s13046-019-1120-4

Internet

http://link.springer.com/article/10.1186/s13046-019-1120-4

Similar Items